No Data
No Data
D. Boral Capital Initiates Coverage On Context Therapeutics With Buy Rating, Announces Price Target of $9
Context Therapeutics Analyst Ratings
H.C. Wainwright Maintains Context Therapeutics(CNTX.US) With Buy Rating, Maintains Target Price $5
Promising Preclinical Data and Strategic Trial Design Support Buy Rating for Context Therapeutics
Context Therapeutics: A Promising Investment in Innovative Oncology Therapies With Strong Financial Position
H.C. Wainwright Maintains Context Therapeutics(CNTX.US) With Buy Rating, Cuts Target Price to $5
No Data
No Data